RGDXQ Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 mai 2023 @ 18:32):

Stats
Dagens volum	77 000.00
Gjennomsnittsvolum	0.00
Markedsverdi	116.00
EPS	$-0.108 ( 2015-03-31 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Volum Korrelasjon

Lang: -0.48 (neutral)

Kort: 0.00 (neutral)

Signal:(51.968) Neutral

Response Genetics, Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Response Genetics, Inc Korrelasjon - Valuta/Råvare

0.00
( neutral )

Response Genetics, Inc Økonomi

Annual	2015
Omsetning:	$18.04M
Bruttogevinst:	$3.94M (21.85 %)
EPS:	$-0.521

FY	2015
Omsetning:	$18.04M
Bruttogevinst:	$3.94M (21.85 %)
EPS:	$-0.521

FY	2014
Omsetning:	$16.72M
Bruttogevinst:	$6.71M (40.12 %)
EPS:	$-0.350

FY	2013
Omsetning:	$19.80M
Bruttogevinst:	$9.35M (47.20 %)
EPS:	$-0.240

Financial Reports:

No articles found.

Response Genetics, Inc

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.